❌

Normal view

ForestPrune: High-ratio Visual Token Compression for Video Multimodal Large Language Models via Spatial-Temporal Forest Modeling

arXiv:2603.22911v1 Announce Type: cross Abstract: Due to the great saving of computation and memory overhead, token compression has become a research hot-spot for MLLMs and achieved remarkable progress in image-language tasks. However, for the video, existing methods still fall short of high-ratio token compression. We attribute this shortcoming to the insufficient modeling of temporal and continual video content, and propose a novel and training-free token pruning method for video MLLMs, termed ForestPrune, which achieves effective and high-ratio pruning via Spatial-temporal Forest Modeling. In practice, ForestPrune construct token forests across video frames based on the semantic, spatial and temporal constraints, making an overall comprehension of videos. Afterwards, ForestPrune evaluates the importance of token trees and nodes based on tree depth and node roles, thereby obtaining a globally optimal pruning decision. To validate ForestPrune, we apply it to two representative video MLLMs, namely LLaVA-Video and LLaVA-OneVision, and conduct extensive experiments on a bunch of video benchmarks. The experimental results not only show the great effectiveness for video MLLMs, e.g., retaining 95.8% average accuracy while reducing 90% tokens for LLaVA-OneVision, but also show its superior performance and efficiency than the compared token compression methods, e.g., +10.1% accuracy on MLVU and -81.4% pruning time than FrameFusion on LLaVA-Video.

TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation

Oncogene, Published online: 24 March 2026; doi:10.1038/s41388-026-03728-6

TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation

Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer

23 March 2026 at 18:00

J Inflamm Res. 2026 Mar 17;19:581764. doi: 10.2147/JIR.S581764. eCollection 2026.

ABSTRACT

Immune checkpoint inhibitors (ICIs) have significantly improved the clinical outcomes for patients with non-small cell lung cancer (NSCLC). However, patient heterogeneity and the limitations of current biomarkers contribute to variations in therapeutic responses. Identifying potential beneficiaries of immunotherapy and predicting efficacy remain critical challenges. In recent years, artificial intelligence (AI) has become increasingly applied in cancer treatment, particularly for modeling clinical data and predicting patient prognosis. By integrating multi-omics data such as radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics, AI enables comprehensive biomarker discovery and facilitates prediction of immunotherapy responses and potential toxicities in NSCLC patients. Despite these advancements, challenges such as data standardization, limited interpretability, and technical barriers persist. This review summarizes the application of AI in predicting immunotherapy efficacy for NSCLC patients and discusses the challenges and future directions in the context of precision medicine.

PMID:41867453 | PMC:PMC13005593 | DOI:10.2147/JIR.S581764

❌